Inventor · disambiguated record
Hongxi Xu
Also filed as: XU HONGXI
7 granted patents·14 pending applications·1 citations·filing 2013–2016
70Inventor score
Files withUNIV HONG KONG BAPTIST15UNIV HONG KONG BAPTIST UNIV5SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE1
Top patents by PatentIndex Score
21 records- 0164US9868716B2Method for preventing and/or treating a subject suffering from asthmaUNIV HONG KONG BAPTIST UNIV·Filed 2015·Granted Jan 16, 2018·1 cites·4 claims
- 0261US9339488B2Anti-cervical cancer compound and method of use thereofUNIV HONG KONG BAPTIST·Filed 2014·Granted May 17, 2016·0 cites·4 claims
- 0360US9408811B2Pharmaceutical composition comprising guttiferone F for the treatment of prostate cancerUNIV HONG KONG BAPTIST UNIV·Filed 2014·Granted Aug 9, 2016·0 cites·8 claims
- 0458US9775857B2Lignans isolated from Lasia spinosa (L.) ThwaitUNIV HONG KONG BAPTIST UNIV·Filed 2016·Granted Oct 3, 2017·0 cites·7 claims
- 0553US2014235877A1Compounds, methods of preparation and use thereof for treating cancerUNIV HONG KONG BAPTIST·Filed 2014·Application pending·0 cites
- 0651US2014194529A1Usage of natural compound for treating inflammation and cancerUNIV HONG KONG BAPTIST·Filed 2014·Application pending·0 cites
- 0750US2013210906A1Compounds, methods of preparation and use thereof for treating cancerUNIV HONG KONG BAPTIST·Filed 2013·Application pending·0 cites
- 0849US2014194528A1Usage of sodium houttuyfonate on inhibiting idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosisUNIV HONG KONG BAPTIST·Filed 2014·Application pending·0 cites
- 0948US2014194530A1Usage of oblongifolin c, a natural compound from garcinia yunnanensis hu, on treating cancer as metastasis inhibitor and autophagic flux inhibitorUNIV HONG KONG BAPTIST·Filed 2014·Application pending·0 cites
- 1047US9408828B2(+)-3′-angeloyloxy-4′-keto-3′,4′-dihydroseselin for treating inflammationUNIV HONG KONG BAPTIST UNIV·Filed 2015·Granted Aug 9, 2016·0 cites·6 claims
- 1147US2015196612A1Anti-enterovirus 71 steroidal saponins and their preparationSHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE·Filed 2014·Application pending·0 cites
- 1247US2015011646A1Usage of guttiferone k, a natural compound from garcinia yunnanensis hu on treating high metastatic esophageal cancerUNIV HONG KONG BAPTIST·Filed 2014·Application pending·0 cites
- 1345US8652540B2Method of using rhein for treating fibrotic conditions and tumorsUNIV HONG KONG BAPTIST·Filed 2013·Granted Feb 18, 2014·0 cites·5 claims
- 1445US2013344174A1Bioactive Fractions and Compounds from Polygonum genus, their Use in Anti-diarrhea and the Method of PreparationUNIV HONG KONG BAPTIST·Filed 2013·Application pending·0 cites
- 1545US2014200265A1Usage of 1,3,5,7-tetrahydroxy-8-isoprenylxanthone for treating inflammationUNIV HONG KONG BAPTIST·Filed 2014·Application pending·0 cites
- 1643US9260466B2Use of a flavanol glycoside for suppressing activation of stellate cellsUNIV HONG KONG BAPTIST·Filed 2013·Granted Feb 16, 2016·0 cites·6 claims
- 1743US2014194499A1Polyprenylated Benzoylphloroglucinols With Anticancer ActivityUNIV HONG KONG BAPTIST·Filed 2014·Application pending·0 cites
- 1843US2014194498A1Polyisoprenylated tetracyclic xanthone with anticancer activityUNIV HONG KONG BAPTIST·Filed 2014·Application pending·0 cites
- 1943US2013210907A1Method for preventing or treating enterochromaffin cell hyperplasia-related diseases by quercetin administrationUNIV HONG KONG BAPTIST·Filed 2013·Application pending·0 cites
- 2040US2017035824A1Usage of oblongifolin c, a natural compound from garcinia yunnanensis hu, on treating cancer as metastasis inhibitor and autophagic flux inhibitorUNIV HONG KONG BAPTIST UNIV·Filed 2016·Application pending·0 cites
- 2136US2015231090A1Usage of guttiferone k for treating high metastatic cancerUNIV HONG KONG BAPTIST·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hongxi Xu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →